Trials / Completed
CompletedNCT00239902
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
Two-year Extension of a One-year, Multicenter, Randomized, Partially-blinded Study of the Safety and Efficacy of FTY720 Combined With Corticosteroids and Full or Reduced-dose Cyclosporine, USP [Modified] (Novartis Brand) in de Novo Adult Renal Transplant Recipients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 396 (planned)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- —
Summary
This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FTY720 |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2004-11-01
- First posted
- 2005-10-17
- Last updated
- 2011-11-02
Source: ClinicalTrials.gov record NCT00239902. Inclusion in this directory is not an endorsement.